Thursday | 4 December, 2008
Australian Biotechnology News
Biotech briefs
Molloy joins Viralytics
Staff Writers 29/09/2008 15:45:00

Former Biota CEO Peter Molloy has been appointed a non-executive director of Sydney biotech Viralytics (ASX: VLA).

Viralytics is in Phase 1 trials of an oncolytic virus technology called Cavatak in late-stage metastatic melanoma patients and another in prostate cancer.

Molloy is now a US-based industry consultant.

Additional Resources
Newsletter Subscription
Sign up for our Australian Life Scientist newsletters!
 
Sponsored Links